BlackRock’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.85M | Sell |
3,616,962
-30,144
| -0.8% | -$74.8K | ﹤0.01% | 3641 |
|
|
2025
Q4 | $6.56M | Buy |
3,647,106
+96,078
| +3% | +$196K | ﹤0.01% | 3715 |
|
|
2025
Q3 | $7.88M | Buy |
3,551,028
+181,358
| +5% | +$295K | ﹤0.01% | 3572 |
|
|
2025
Q2 | $4.99M | Buy |
3,369,670
+3,115,135
| +1,224% | +$6.37M | ﹤0.01% | 3778 |
|
|
2025
Q1 | $652K | Buy |
254,535
+29,878
| +13% | +$71.3K | ﹤0.01% | 4319 |
|
|
2024
Q4 | $422K | Buy |
224,657
+45,873
| +26% | +$64.9K | ﹤0.01% | 4454 |
|
|
2024
Q3 | $182K | Sell |
178,784
-154,387
| -46% | -$162K | ﹤0.01% | 4544 |
|
|
2024
Q2 | $390K | Sell |
333,171
-2,977,346
| -90% | -$3.52M | ﹤0.01% | 4407 |
|
|
2024
Q1 | $4.17M | Sell |
3,310,517
-147,217
| -4% | -$220K | ﹤0.01% | 3746 |
|
|
2023
Q4 | $6.15M | Buy |
3,457,734
+282,272
| +9% | +$439K | ﹤0.01% | 3606 |
|
|
2023
Q3 | $5.27M | Buy |
3,175,462
+534,491
| +20% | +$959K | ﹤0.01% | 3638 |
|
|
2023
Q2 | $5.28M | Buy |
2,640,971
+2,524,828
| +2,174% | +$6.02M | ﹤0.01% | 3708 |
|
|
2023
Q1 | $244K | Buy |
116,143
+14,250
| +14% | +$25K | ﹤0.01% | 4722 |
|
|
2022
Q4 | $140K | Buy |
101,893
+3,130
| +3% | +$3.43K | ﹤0.01% | 4949 |
|
|
2022
Q3 | $103K | Sell |
98,763
-2,790
| -3% | -$3.09K | ﹤0.01% | 5167 |
|
|
2022
Q2 | $111K | Sell |
101,553
-7,508
| -7% | -$8.78K | ﹤0.01% | 5215 |
|
|
2022
Q1 | $116K | Sell |
109,061
-5,337
| -5% | -$4.89K | ﹤0.01% | 5253 |
|
|
2021
Q4 | $95K | Sell |
114,398
-5,157
| -4% | -$5.4K | ﹤0.01% | 5283 |
|
|
2021
Q3 | $159K | Sell |
119,555
-2,944
| -2% | -$4.47K | ﹤0.01% | 5034 |
|
|
2021
Q2 | $234K | Buy |
122,499
+121,128
| +8,835% | +$417K | ﹤0.01% | 4870 |
|
|
2021
Q1 | $6K | Buy |
+1,371
| New | +$6.38K | ﹤0.01% | 5125 |
|
|
2020
Q4 | – | Sell |
-6,284
| Closed | -$24K | – | 5151 |
|
|
2020
Q3 | $24K | Hold |
6,284
| – | – | ﹤0.01% | 4695 |
|
|
2020
Q2 | $24K | Buy |
+6,284
| New | +$21.5K | ﹤0.01% | 4670 |
|
|
2017
Q4 | – | Sell |
-9,420
| Closed | -$55K | – | 4994 |
|
|
2017
Q3 | $55K | Hold |
9,420
| – | – | ﹤0.01% | 4462 |
|
|
2017
Q2 | $79K | Sell |
9,420
-810
| -8% | -$7.6K | ﹤0.01% | 4444 |
|
|
2017
Q1 | $139K | Buy |
+10,230
| New | +$92K | ﹤0.01% | 4280 |
|
|
2015
Q2 | – | Sell |
-33,956
| Closed | -$604K | – | 3261 |
|
|
2015
Q1 | $604K | Hold |
33,956
| – | – | ﹤0.01% | 1488 |
|
|
2014
Q4 | $625K | Hold |
33,956
| – | – | ﹤0.01% | 1296 |
|
|
2014
Q3 | $822K | Sell |
33,956
-2,750
| -7% | -$79.2K | ﹤0.01% | 1250 |
|
|
2014
Q2 | $1.34M | Hold |
36,706
| – | – | ﹤0.01% | 1132 |
|
|
2014
Q1 | $1.68M | Hold |
36,706
| – | – | ﹤0.01% | 1081 |
|
|
2013
Q4 | $1.43M | Buy |
+36,706
| New | +$1.55M | ﹤0.01% | 1098 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
BlackRock's PLX Position: Q1 2026 in Review
BlackRock reduced its Protalix BioTherapeutics (PLX) stake by 0.83% in Q1 2026, selling an estimated $74.8K and leaving 3,616,962 shares worth $7.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3641.
BlackRock first reported a position in PLX in Q4 2013 and has held it in 32 quarters since. The position peaked at $7.88M in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- BlackRock held 3,616,962 shares of Protalix BioTherapeutics worth $7.85M as of Q1 2026.
- BlackRock sold 30,144 Protalix BioTherapeutics shares in Q1 2026, an estimated $74.8K.
- Protalix BioTherapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3641 holding.
- BlackRock first reported a position in Protalix BioTherapeutics in Q4 2013 and has held it in 32 quarters since.
- BlackRock's Protalix BioTherapeutics position peaked at $7.88M in Q3 2025.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.